Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists initially developed for type 2 diabetes management. Both are now FDA-approved for weight loss in adults with obesity or overweight with comorbidities. Semaglutide (brand names Wegovy for weight loss, Ozempic for diabetes) activates GLP-1 receptors; tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors, offering a dual mechanism.

Understanding the mechanism, clinical evidence, and individual genetic predispositions helps patients and providers make informed decisions. PlexusDx emphasizes precision wellness by offering both compounded options alongside optional genetic testing that reveals predispositions in peptide pathways—enabling more personalized conversations with your healthcare team about which mechanism may align with your metabolic profile.

Mechanism of Action: GLP-1 Monotherapy vs Dual GLP-1/GIP Targeting

Semaglutide works by stimulating GLP-1 receptors in the brain and pancreas, increasing insulin secretion, slowing gastric emptying, and promoting satiety. This monotherapy approach has been studied extensively since the 1980s. Tirzepatide's dual mechanism simultaneously activates GLP-1 and GIP pathways, theoretically offering additive metabolic benefits including enhanced insulin secretion and appetite suppression.

Clinical trials show tirzepatide produces greater weight loss than semaglutide at comparable doses. SURMOUNT-1 (tirzepatide) reported up to 22.5% weight loss at 52 weeks; STEP trials (semaglutide) showed up to 17.4% at 68 weeks. Individual response varies considerably, influenced by baseline metabolic markers, genetic factors, and adherence patterns rather than mechanism alone.

Comparative Clinical Profile: Efficacy, Dosing, and Gastrointestinal Tolerability

Both medications require dose escalation over 16–20 weeks to minimize gastrointestinal side effects. Semaglutide reaches a maintenance dose of 2.4 mg weekly; tirzepatide reaches 15 mg weekly. Nausea, vomiting, and constipation occur in most patients but typically improve with dose titration and dietary adjustment. Long-term cardiovascular outcomes differ: semaglutide demonstrated cardiovascular benefit in SELECT (2024); tirzepatide's CV data are still accumulating.

Factor Semaglutide (GLP-1 only) Tirzepatide (GLP-1 + GIP)
Receptor Target GLP-1 agonist Dual GLP-1 and GIP agonist
Average Weight Loss (52 weeks) Up to 17.4% Up to 22.5%
Maintenance Dose 2.4 mg weekly subcutaneous 15 mg weekly subcutaneous
Primary GI Side Effects Nausea, vomiting, constipation Nausea, vomiting, constipation (higher incidence initially)
Cardiovascular Evidence Demonstrated CV benefit (SELECT) Ongoing; CV data limited as of 2024
Compounded Cost Range (PlexusDx) $179–$229/month $229–$309/month

Genetic Predispositions and Individual Response Variability in Peptide Pathways

Response to GLP-1 and GIP agonists is not uniform across populations. Genetic variants in GLP1R, GIPR, FTO, and MC4R genes may influence baseline receptor sensitivity, appetite regulation, and metabolic flexibility. For example, individuals with specific FTO variants show varying baseline metabolic rate; GIPR rs1800437 variants correlate with differential GIP receptor expression and potentially tirzepatide response patterns.

PlexusDx Precision Peptide Genetic Test examines predispositions across four key peptide pathway genes, providing context for clinical conversations with your provider. Testing may reveal why certain mechanisms—semaglutide's GLP-1 focus versus tirzepatide's dual approach—might align better with your genetic profile. This should be interpreted alongside your metabolic markers, BMI trajectory, and clinical history, not as a prediction of guaranteed response.

Safety, Contraindications, and Provider-Guided Selection Criteria

Both semaglutide and tirzepatide carry absolute contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. Relative cautions include severe renal impairment, acute pancreatitis history, and diabetic retinopathy requiring laser treatment. Dehydration and concurrent diuretic use increase risk of acute kidney injury, especially during dose escalation when GI side effects peak.

Provider selection typically considers baseline A1C (if diabetic), BMI, GI tolerance history, cardiovascular risk profile, and cost/access. Genetic testing of peptide pathways may add clinical context by revealing predispositions that inform mechanism selection. Compounded options from licensed 503A pharmacies like those used by PlexusDx offer cost-effective access; starting with a qualified provider conversation—whether telehealth or in-person—ensures safety monitoring, dose titration, and adjustment based on individual response rather than genetic prediction alone.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes to reveal predispositions in your peptide signaling pathways. This may help provide context about baseline receptor sensitivity, appetite-regulation capacity, and metabolic flexibility—factors that influence how your body may respond to GLP-1 monotherapy versus dual GLP-1/GIP approaches. Results should always be interpreted with a qualified healthcare provider, not as deterministic predictions of medication efficacy.

The genetic test costs $99 as an add-on with any PlexusDx medication order or $298 standalone. It predicts predispositions in peptide genetic pathways—not pharmacogenomic drug metabolism or exact semaglutide or tirzepatide response. Knowing your genetic background in these pathways can support a more personalized conversation with your provider about which mechanism (monotherapy versus dual-action) may align with your metabolic tendencies and clinical goals.

PlexusDx combines compounded semaglutide ($179–$229/month) and tirzepatide ($229–$309/month) with optional genetic testing to support precision wellness conversations. A qualified provider evaluates your safety, contraindications, baseline metabolic markers, and genetic context together—not genetics alone—to guide selection. This multi-factor approach respects individual variability and emphasizes evidence-based personalization alongside affordability through licensed 503A compounding pharmacies.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves